Koers Anavex Life Sciences Corp OTC Bulletin Board
Aandelen
AVXL
US0327971026
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 316 mln. 294 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -46 mln. -42,75 mln. | Nettowinst (verlies) 2025 * | -55 mln. -51,11 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-6,75
x | K/w-verhouding 2025 * |
-6,02
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,86% |
Recentste transcriptie over Anavex Life Sciences Corp
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 05-07-13 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 01-10-15 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 05-07-13 | |
Tom Skarpelos
FOU | Founder | 57 | 23-01-04 |
Jiong Ma
CHM | Chairman | 60 | 25-05-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+6,79% | 14,16 mld. | |
+38,61% | 12,63 mld. |
- Beurs
- Aandelen
- Koers AVXL
- Koers AVXL